Cryopreservation of ex vivo Cell and Gene Therapies

13:40 - 14:15

  • ex vivo stem cell therapies for ultra-rare diseases.
  • Current formulation has a limited shelf life restricting patient accessibility and release strategy.
  • A change to a cryoformulation will increase the shelf life to months/years
  • Careful assessment of the CQAs is vital along with comprehensive comparability

Richard Zajicek, Head of Formulation Development, Cell and Gene Therapy Group, GSK